Overview

A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Status:
Active, not recruiting

Trial end date:
2022-06-06

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the efficacy, safety, and immunogenicity of ABP 654 compared with ustekinumab in participants with moderate to severe plaque psoriasis.

Phase:

Phase 3

Details

Lead Sponsor:

Amgen

Treatments:

Ustekinumab